LSD - SAM Posting.pdf

LIMITED SOURCES DOCUMENTATION (DEC 2018)

Required for Limited Source Acquisitions Over $10,000 but not Exceeding $250,000

Acquisitions that do not allow for competition to the maximum extent practicable must be documented in accordance with Federal Acquisition Regulations {FAR) 13.106-3(b) for open market purchase orders or FAR 8.405-6{0 for Federal Supply Schedule {GSA) orders. Limited source documentation is required in the following circumstances: (1) when soliciting fewer than the minimum number of sources {at least three sources) required by FAR 13.104(b ). 8.405-1( c). or 8.405-2( c){2). whichever is applicable; and (2) when using brand name only specifications.

This template may be used for the documentation described in FAR 8.405-6(b)(2)(i) or 13.106-1(b)(1). The customer shall provide the following information:

Purchase Request Number:

Brand Name Only Description:

□ YES [8J NO

Estimated Amount {inclusive of options):

Recurring Requirement:

□ YES [8J NO

Delivery Date or Period of Performance:

01/24/2024 - 01/23/2025

FSS Contract Number {if applicable):

Brief description of supplies or services required and the intended use:

The Drug and Chemical Evaluation Section (DOE) is seeking to purchase synthetic substances for diversion and control purposes. These substances will be tested for pharmacological activity. There is currently minimal, or no, pharmacological information available about this substance. The data obtained from these studies are necessary to enrich already known information about these substances and/or further support scheduling action documents to permanently place this substance under the control of the Controlled Substances Act (21 USC811 ).

Unique characteristics that limit availability to only one source, and any justification that no other supplies or services can be used or that urgent and compelling circumstances exist - include all critical delivery or performance dates and impact to the government if dates are not met:

The synthetic substances that DEA is seeking to purchase are drug of concern. These substances are known, or have the potential, to be highly abused. DEA is collecting information on how these substances are integrated into the NPS market.

In addition, the purchase of these substances is urgently needed to add to what is already known about this substance and/or support the scheduling of this substance by the DEA. For substances that are not already controlled, any delay will certainly result in the postponement of any DEA action to place these drugs under the control of the Controlled Substances Act, and prolong significant health hazards to the general public.

Cayman Chemical is the only company that provided a quotation for all the substances listed on the DEA-19 form. DEA has an urgent and compelling need to obtain this substance as soon as possible and in acceptable purity.

Describe in detail any market research conducted. Include results and state whether any vendors expressed interest:

Market research was conducted for vendors whom produces synthetic substances. These other vendors were not able to meet the requirement.

The Contracting Officer hereby certifies that:

A. Only one source is reasonably available;

B. An order for the supplies or services will not be placed unless the price is determined to be fair and reasonable; and

C. If brand name specifications are used for the basis of this determination and the acquisition exceeds $25,000, this Limited Source Documentation will be made available together with the solicitation in the Govemmentwide Point of Entry {FedBizOpps) in accordance with FAR 5.102(a)(6). on GSA e-Buy in accordance with FAR 8.405-6(d). or on the NASA SEWP V Quote Request Tool pursuant to 40 U.S.C. 11302{e).